Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22285003 | 0.80 | SLC6A2 (0.65) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL29022140 | 0.80 | SLC6A2 (0.65) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL6926417 | 0.80 | SLC6A2 (0.65) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL10413244 | 0.80 | SLC6A2 (0.65) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL2951055 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL6936570 | 0.79 | SLC6A2 (0.63) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL27505917 | 0.79 | SLC6A2 (0.63) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL1415727 | 0.79 | SLC6A2 (0.63) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL27784843 | 0.78 | SLC6A2 (0.61) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL4584365 | 0.77 | CA1 (0.63) | SLC6A4SLC6A3SLC6A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4346823-A2 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Alto Neuroscience, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022256636-A2 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | ALTO NEUROSCIENCE, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2013064692-A1 | TRIPLE COMBINATION FOR THE TREATMENT OF CANCER | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | SLC6A4 1318/4885SLC6A3 375/4885SLC6A2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.